LOXO-305 CAS No.:2101700-15-4
Pirtobrutinib (LOXO-305, LY3527727, RXC-005) yog ib qho muaj zog thiab xaiv tsis-covalent BTK inhibitor nrog IC50 ntawm 5.69 nM, qhia nanomolar potency tiv thaiv ob hom tsiaj qus thiab C481- hloov BTK
Hauj lwm lawm
Pirtobrutinib (LOXO-305, LOXO305, LY3527727, RXC-005)
Catalog No.Qauv: URK-V963Tsuas yog siv rau Lab.
Pirtobrutinib (LOXO-305, LY3527727, RXC-005) yog ib qho muaj zog thiab xaiv tsis-covalent BTK inhibitor nrog IC50 ntawm 5.69 nM, qhia nanomolar potency tiv thaiv ob hom tsiaj qus thiab C481- hloov BTK
Kev ua lom lom
Pirtobrutinib (LOXO-305, LY3527727, RXC-005) yog ib qho muaj zog thiab xaiv tsis-covalent BTK inhibitor nrog IC50 ntawm 5.69 nM.
LOXO-305 qhia nanomolar potency tawm tsam ob hom tsiaj qus thiab C481-mutated BTK.
LOXO-305 displays >300 quav xaiv ntawm BTK tshaj 98 feem pua ntawm lwm cov kinases, txo cov peev xwm rau kev tawm tsam toxicities.
Pirtobrutinib (LOXO-305) tau raug tsim los tswj kom muaj ntau dua 90 feem pua ntawm qhov siab tshaj plaws BTK inhibition ntawm trough, yog li ua tiav lub hom phiaj zoo inhibition thoob plaws lub sijhawm noj, txawm nyob rau hauv cov qog loj hlob.
Physicochemical Properties
|
M.Wt |
479.436 |
|
|
Formula |
C22H21F4N5O3 |
|
|
CAS Nr. |
2101700-15-4 |
|
|
Cia |
Hmoov hmoov -20 degree 3 xyoos; 4 degree 2 xyoos |
Hauv Solvent -80 degree 6 Lub Hlis -20 degree 1 Lub Hlis |
|
Solubility |
10 mM hauv DMSO |
|
|
Tshuaj npe |
|
|
Cov ntaub ntawv
1. Brandhuber B, et al. Clin. Lymphoma Myeloma Leuk. Xyoo 2018; 18: S216.
2. Ito K, et al. Eur J Cancer. 2021 Mar; 145:183-193.
URK-V963_COAURK-V963_SDSURK-V963_TDSNco tseg: Tag nrho cov khoom ntawm Ureiko tsuas yog siv rau kev tshawb fawb tshawb fawb lossis kev tshaj tawm daim ntawv pov thawj tshuaj, thiab peb tsis muab cov khoom thiab cov kev pabcuam rau kev siv tus kheej!
Cim npe nrov: loxo-305 cas no.:2101700-15-4
Xa kev nug
Koj Tseem Yuav Zoo Li
